# Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

> **NCT01591863** · PHASE2 · COMPLETED · sponsor: **Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 38 (actual)

## Conditions studied

- Clostridium Difficile-associated Diarrhea

## Interventions

- **DRUG:** fidaxomicin

## Key facts

- **NCT ID:** NCT01591863
- **Lead sponsor:** Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-15
- **Primary completion:** 2014-03-07
- **Final completion:** 2014-03-07
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01591863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01591863, "Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01591863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*